Annual rank23
Sweden · Healthcare
Camurus
Camurus develops and commercialises long-acting medicines for treating severe and chronic diseases.
FY2022–FY2025
FY2022–FY2025
FY2022–FY2025
current context only
Company profile
Long-acting medicines built from a self-forming injection depot
Camurus is a Lund-based biopharmaceutical company built around FluidCrystal, a lipid formulation that changes structure after injection and releases a medicine over days, weeks or months. The platform underpins marketed treatments for opioid dependence and acromegaly, a clinical pipeline in endocrine, metabolic and oncology-related conditions, and partnerships that pair Camurus' delivery technology with other companies' active compounds.
Drug-delivery technology
A liquid injection assembles its own medicine depot
FluidCrystal combines endogenous polar lipids with an active substance. After subcutaneous injection, contact with tissue fluid turns the liquid into a crystalline gel; the matrix then degrades gradually and releases the medicine. Camurus tunes the composition for delivery periods ranging from days to months.
- How FluidCrystal works The lipid matrix, injection process and controllable release profile
- ▶ VideoWatch: the depot forms Camurus' English animation of injection, gel formation and release
- Business model In-house development, direct commercialisation and partnerships
Medicines and markets
One formulation platform, three commercial names
Buvidal provides weekly or monthly buprenorphine injections for opioid dependence in multiple markets. The same product is sold in the US as Brixadi by licensee Braeburn. Oczyesa is a monthly octreotide depot for eligible adults with acromegaly and is designed for self-administration with a prefilled autoinjector pen.
- Product portfolio Buvidal, Brixadi and Oczyesa, with administration formats
- Brixadi in the US The Braeburn licence and weekly or monthly product launch
- Oczyesa authorisation The once-monthly autoinjector and EU treatment setting
- Buvidal market expansion An example of direct European commercialisation in Portugal
Pipeline and partnering
Extend the depot across molecules and disease areas
The pipeline applies long-acting depots to octreotide, semaglutide, setmelanotide, treprostinil and other active substances. Programmes span neuroendocrine tumours, polycystic liver disease, chronic pain, rare genetic obesity and metabolic disease; a Lilly agreement separately covers selected incretin compounds for cardiometabolic health.
- R&D pipeline Named candidates, development stages and target conditions
- Lilly collaboration Long-acting FluidCrystal incretins using selected Lilly compounds
- Monthly semaglutide programme CAM2056 and the planned transition beyond Phase 1b
- CAM2029 regulatory pathway The US review and the broader octreotide development programme
Why dosing routines matter
Stories make chronic treatment burden visible
Camurus' English story library puts the science beside lived experience. Mattias describes opioid dependence that began with prescribed pain relief; Ken recounts an acromegaly diagnosis reached after years of symptoms; Dusty describes learning that an apparent terminal cancer diagnosis was a neuroendocrine tumour she could live with.
- Disease areas Opioid dependence, rare diseases and oncology-related conditions
- Mattias' story When prescribed pain relief developed into opioid dependence
- Ken's story A long path from unexplained symptoms to acromegaly diagnosis
- Dusty's story Living with a gastroenteropancreatic neuroendocrine tumour
Official profile sources: About us — Camurus · FluidCrystal technology
Current 2026 update
What has changed in 2026?
CAM2029 FDA review · 17 July 2026
CAM2029 FDA reviewlatest official update
4company-specific highlights
0%2026 stock return · context only
Product sales
H1 product sales were broadly flat at SEK 955m versus SEK 954m.
Royalty revenue
H1 Brixadi royalty revenue rose to SEK 233m from SEK 163m.
Operating profit
H1 operating profit fell to SEK 461m from SEK 531m.
CAM2029 FDA review
After the FDA issued a Complete Response Letter on the initial CAM2029 filing, it accepted Camurus' resubmission and set 18 December 2026 as the target action date.
Official 2026 sources: Camurus' Interim Report Second Quarter 2026 · 15 July 2026 · Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA · 17 July 2026
Annual record
Ranking history
Future editions add rows; they do not rewrite the 2026 record.
| Edition | Measurement period | Rank | Revenue growth | Net-income growth | Stock return |
|---|---|---|---|---|---|
| 2026 | FY2022–FY2025 | 23 | +144% | +1265% | +144% |